CoChat

Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus

Iwasaki, Tomoyuki, Yoneda, Masato, Inamori, Masahiko, Shirakawa, Jun, Higurashi, Takuma, Maeda, Shin, Terauchi, Yasuo, Nakajima, Atsushi · 2011 · Hepatogastroenterology
Cited by 124

The DOI matches its Crossref record.

Abstract

BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury, and is considered as the hepatic manifestation of metabolic syndrome. However, no effective drug therapy for NAFLD has been established yet. In the present study, we evaluated the efficacy of 4 months of treatment with sitagliptin in NAFLD patients with type 2 diabetes mellitus (DM). METHODOLOGY: We evaluated 30 NAFLD patients with type 2 DM. NAFLD was diagnosed by ultrasonography. The patients were administered sitagliptin (50mg/body/day) for 4 months. RESULTS: significant decreases of the plasma glucose and serum HbA1c, AST, ALT and γ-GTP levels were observed after 4 months of treatment with sitagliptin. CONCLUSIONS: In this study, not only the parameters of diabetes, but also those of liver tests were improved by the treatment with sitagliptin. Our study demonstrated the efficacy of sitagliptin in NAFLD patients with type 2 DM, suggesting that a large-scale clinical trial is warranted in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5754/hge11263

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 124

Metadata

Authors
Iwasaki, T., Yoneda, M., Inamori, M., Shirakawa, J., Higurashi, T., Maeda, S., Terauchi, Y., & Nakajima, A.
Venue
Hepatogastroenterology
Published
2011-10-12
Volume
58
Issue
112
Pages
2103-5
ISSN
0172-6390 (ISSN-L)
OpenAlex
W2026049223
Cited by
124
References
0
FWCI
6.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.5754/hge11263
The paper
Iwasaki, T., Yoneda, M., Inamori, M., Shirakawa, J., Higurashi, T., Maeda, S., Terauchi, Y., & Nakajima, A. (2011). Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus. Hepatogastroenterology. https://doi.org/10.5754/hge11263

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.